Overview
France robotic therapies maker's Q4 revenue beat analyst expectations, driven by HIFU segment growth
Company-wide Q4 revenue fell 7% yr/yr as non-core business revenue declined
Company reiterated 2026 revenue guidance, expects HIFU revenue to grow 34%-45% yr/yr
Outlook
EDAP reiterates 2026 revenue guidance of $72.0 mln to $80.0 mln
Company expects 2026 HIFU revenue between $50.0 mln and $54.0 mln, up 34%-45% YoY
EDAP says demand for Focal One systems remains strong across academic and community centers
Result Drivers
HIFU SYSTEM SALES - Q4 HIFU revenue rose 34% yr/yr, driven by record Focal One system placements and strong demand in academic and community hospitals, per CEO Ryan Rhodes
PROCEDURE GROWTH - U.S. Focal One procedure volume grew 28% yr/yr, supporting higher disposables revenue
GROSS MARGIN PRESSURE - Gross margin declined due to tariffs on imports from France and an inventory reserve for legacy parts
Company press release: ID:nGNE1rGnn4
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | EUR 18.94 mln | EUR 18.36 mln (3 Analysts) |
Q4 Net Income | -EUR 8.19 mln | ||
Q4 Basic EPS | -EUR 0.22 | ||
Q4 Gross Profit | EUR 8.06 mln | ||
Q4 Operating Expenses | -EUR 13.23 mln | ||
Q4 Operating Income | -EUR 5.16 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Edap Tms SA is $4.00, about 2.3% above its March 24 closing price of $3.91
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)